What’s Next for Viking Therapeutics?

Overview of Viking’s Obesity-Drug Program

Viking Therapeutics Inc. (VKTX) is making significant strides in its obesity-drug program, particularly with its oral drug VK2735. Following a positive note from Oppenheimer, the company’s stock surged by 3%, reflecting analysts’ optimism about potential partnerships with larger pharmaceutical players. With clinical trials currently in progress, management is exploring ways to scale up production should these trials yield successful results.

Progress on VK2735

Viking is currently conducting a phase 2a dosing trial of VK2735, with data expected to be released in the latter half of the year. Furthermore, the company plans to initiate a phase 3 trial for an injectable version of VK2735 in the first half. Notably, the oral formulation is anticipated to be a groundbreaking advancement in the obesity treatment sphere, as it caters to a common patient preference for pills over injections. Presently, most obesity and diabetes drugs on the market, such as those from Eli Lilly & Co. (LLY) and Novo Nordisk (NVO), are only available in injectable form.

Management and Partnership Opportunities

During discussions with analysts, Viking’s management expressed an interest in pursuing partnerships, ideally through global licensing and royalty agreements with a prominent cardiometabolic leader. This desire for collaboration aligns with the broader industry trend of pharmaceutical companies seeking synergies to bolster drug pipelines.

Viking has been regarded as an attractive acquisition target, especially following the promising data released from early VK2735 trials. In their latest update presented at Obesity Week, the company reported that adults with obesity who took a 100 mg dose of VK2735 demonstrated an average weight loss of 8.2% over four weeks. Comparatively, weight loss for participants taking a placebo reached only 6.8%.

Analyst Sentiment and Future Trials

Viking’s stock boasts a perfect score, with buy ratings from all 14 analysts currently covering the company according to FactSet. This unanimous support highlights the unique clinical profile and expansive market potential of VK2735. Analysts from Oppenheimer remain enthusiastic about the upcoming results from the phase 2a trial, looking forward to insights into various dosing arms and an exploratory arm focusing on a 30 mg maintenance dose following an up-titration to 90 mg.

These trials will test five active arms, with doses ranging from 15 mg to 120 mg and titration beginning at 30 mg for certain cohorts. Oppenheimer has expressed particular interest in seeing how these trials unfold, as they could have significant implications for VK2735’s global competitiveness in the weight-loss market.

Beyond Obesity: The Broader Pipeline

In addition to its obesity drug, Viking’s portfolio includes treatments for non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, which afflicts approximately 22 million Americans. This condition may lead to severe consequences such as end-stage liver disease and liver cancer, making it a critical area of focus in the healthcare sector. With escalating incidence rates, NASH presents a lucrative opportunity for the company.

Furthermore, Viking’s amylin program, expected to enter phase 1 trials later this year, is garnering attention. This hormone, responsible for regulating blood sugar, has shown promising weight-loss signals in preclinical studies. Analysts from Oppenheimer are closely monitoring the development of this program, which could prove to be a pivotal addition to Viking’s expanding obesity pipeline.

Stock Performance and Investment Outlook

Viking’s stock has experienced substantial growth, rallying by a striking 51% in the past year, significantly outpacing the SPDR S&P Biotech ETF (XBI) which posted a modest 4% increase, and the S&P 500 (SPX) which rose by 25%. This performance is underscoring investors’ growing confidence in the company’s future prospects.

In conclusion, Viking Therapeutics stands on the cusp of exciting developments in the obesity treatment landscape and beyond. As clinical trials progress and potential partnerships emerge, the optimism surrounding VK2735 and the company’s broader therapeutic pipeline is likely to fuel continued interest from investors and industry experts alike.

DISCLAIMERS – THIS IS A PAID ADVERTISEMENT.

TipsForTraders.com

This is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public and private companies. By reading this email, our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing.

This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.

For a full disclaimer & disclosure please click here.

This communication is a paid advertisement and is not a recommendation to buy or sell securities. IR PUB Network, and its owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled companies or a third party to disseminate this communication. IThis compensation is a major conflict with our ability to be unbiased, more specifically: This communication is for entertainment purposes only. Never invest purely based on our communication.

Gains mentioned in this article, in our newsletter and on our website may be based on end-of-day or intraday data. Therefore, this communication should be viewed as a commercial advertisement only. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, IR PUB Network often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, and approved by the company that is featured herein, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s).

You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. We have not thoroughly investigated the background of any of the companies we profile. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct.

NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation.

ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our featured profiles on Companies. Gains mentioned in our website / media webpage(s) may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this message and the product materials are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher.

Blog